0001104659-24-032384.txt : 20240308 0001104659-24-032384.hdr.sgml : 20240308 20240308160542 ACCESSION NUMBER: 0001104659-24-032384 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240306 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33958 FILM NUMBER: 24734323 BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 8-K 1 tm248331d1_8k.htm FORM 8-K
false 0001390478 0001390478 2024-03-06 2024-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): March 6, 2024

 

 

 

SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33958   20-8099512
(State or other jurisdiction of
incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)
         
    7 Times Square, Suite 2503
 New York, NY 10036		    
    (Address of Principal Executive
Offices) (Zip Code)		    
         
Registrant’s telephone number, including area code: (646) 200-5278

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per share SLS The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 6, 2024, Barbara A. Wood, Executive Vice President, General Counsel and Corporate Secretary of SELLAS Life Sciences Group, Inc. (the “Company”), was terminated without cause, effective April 15, 2024. The Company expects to enter into a separation agreement and release of claims with Ms. Wood, the terms of which will be disclosed once available.

 

In addition, on March 6, 2024, Robert Francomano, Senior Vice President and Chief Commercial Officer of the Company, was terminated without cause, effective March 31, 2024. The Company expects to enter into a separation agreement and release of claims with Mr. Francomano, the terms of which will be disclosed once available.

 

Item 8.01Other Events.

 

On March 8, 2024, the Company issued a press release (the “Press Release”) announcing executive leadership reorganization and prioritization of commercialization partnerships. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

 

2

 

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number		   Description
99.1   Press Release dated March 8, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SELLAS Life Sciences Group, Inc.
     
Date: March 8, 2024 By:   /s/ John T. Burns
    Name: John T. Burns
    Title: Senior Vice President, Chief Financial Officer

  

4

 

 EX-99.1 2 tm248331d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

NEWS RELEASE

 

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

 

3/8/2024

 

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has streamlined its executive leadership to further focus on advancing the Company’s clinical programs while optimizing resource allocation. As part of this effort, Senior Vice President, Chief Commercial Officer, Robert Francomano and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood, will be departing the Company.

 

“As part of our efforts to rapidly advance our clinical pipeline, we continue to streamline our operations to effectively and efficiently deliver on our key business objectives,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “As I mentioned on the January shareholder call, our focus remains on shareholder value through the development of our assets and tight financial stewardship and exploration of commercial partnerships with the assistance of Stifel Financial Corp. I am confident that SELLAS has the right leadership in place to drive forward all of our clinical programs and I look forward to upcoming interim analysis of the Phase 3 REGAL trial of GPS in AML and reporting topline data from our Phase 2a SLS009 r/r AML trial this quarter and additional data in the second quarter, and topline data from the Phase 1b/2 study of SLS009 in PTCL in the second quarter. Additionally, we made significant strides in commercial market access, pricing strategies, and reimbursement initiatives positioning SELLAS for continued success in the Phase 3 REGAL trial of GPS and its potential as a new treatment for AML patients.”

 

Dr. Stergiou continued: “I would like to thank Robert and Barbara for their leadership, dedication, and unwavering contributions to help bring SELLAS to this point of development. I wish them the very best in their future endeavors.”

 

In line with the Company’s commitment to maintaining operational excellence, SELLAS is engaging the expertise of a seasoned commercial consultant with a proven track record of success, including launching Venetoclax. Stacy Yeung, recently promoted to Vice President, Associate General Counsel, and Head of Compliance, with 20 years of relevant experience will lead the Company’s legal and compliance functions.

 

 

 

About SELLAS Life Sciences Group, Inc.

 

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009), a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit www.sellaslifesciences.com.

 

Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program and the timing for achievement of milestones. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 16, 2023 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

 

Investor Contact

 

Bruce Mackle

Managing Director

LifeSci Advisors, LLC

SELLAS@lifesciadvisors.com

 

Source: SELLAS Life Sciences Group, Inc.

 

 

 EX-101.SCH 3 sls-20240306.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sls-20240306_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sls-20240306_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm248331d1_ex99-1img001.jpg GRAPHIC begin 644 tm248331d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" !9 /8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]]M0U+ M&6YNIHK:V@4O)+*X1(U'4DG@"O#M1_X*C^-]7_8(U$^")+J.6UU%)]8%N6$DFG"VN1(HQS]\Q?E7X ME_L(_LCZ=^VC\6SX,G\;Z=X,U6ZC!TPWULTL=_)DYC# C:W3'KFOO.'.%,)C ML#/'XNLXQB]HJ[7F]_R/@>).+,7@C_ _ MZ*?H'_?$W_Q%'_#T?X ?]%/T#_OB;_XBOS>_XA=_&7_14/#G_@NF_P#BJ/\ MB%V\9?\ 13_#G_@NF_\ BJW_ +%X7_Z#9?=_]J8?VWQ3_P! 4?O_ /MC]6O@ MC^UE\.OVC[V_M_ _BK3_ !%-IB+)=);+(/)5N%)W*.N.U=GXJ\7:7X&\/W6J MZSJ%II>FV2&2>ZNI1'%$HZDL>!7QA_P25_X)1ZW_ ,$Y?%'B^_U;Q5IGB)/$ MEM!;QK:VSQ&(QLS$G<3US7(_\'(OBW4- _8HTVRM+F6WMM5U=(KI4;'FJNTA M3[<]*^?64X3$9M' X*KS4Y-)2:\M=-#Z!YOB\/E$\?CJ7+4BFW%/STUU/HYO M^"IW[/R,0?B?H.0<']W/_P#&Z3_AZA^S[_T4_0O^_<__ ,;K\?\ _@G[_P $ M1-5_;T_9_A\=67CRP\/QRWDUI]DFTYIROEL5W;@XZXZ8KV\?\&N'B/\ Z*QH M_P#X)Y/_ (Y7TN)X>X;P]65"MBY*479JW7_P$^9PW$7$V(I1KT<'%QDKIWZ? M^!'Z(_\ #T_]GW_HI^A?]^Y__C=>A? []J3P!^TG%?/X&\367B)=,8)=&W21 M1$2 1G?^%'LY3F M>?U<5&GC<+&%/6[3OT_Q,^E_C#\::W5PL1RS7F?,I\MM+=/ MF=,L]K+/8Y5RKE<.:^M^OR/TFHH%%?,'U(5Y3\9_VX?A3^SSXH_L7QGXST[0 M=4\D7 MYXI68QGH?E0C^M>JGFOP:_P"#D3_D^JT_[ L'_H*U]'PMDM+-,=]5 MK2<59NZ\O4^;XJSJKE6!^M48J3NE9^?H?NYHNM6OB+2;:^LIEN+2\C6:&5>D MB,,@C\*M5Q/[-PQ\ ?!G_8'MO_1:UVU>!5CR3<5T9]!2FYTXS?5!11169H&: M\J_::_;<^%O['6G65S\1_%MKX;347V6R&UN+N64^HC@C=\?[1&/>O4Y'$2%F M(55!)). !7\YO_!0#XG>)O\ @I7_ ,%!_$%MX3BGUF.V>XM=%M5?C[+;1N[N M.P)2,L?I7U'"N00S3$25>7+3@KR:_#5Z+_@'RW%?$,\JP\70CS5)NT4[_/1: MO_@G]!?P=^-?A7]H#P):>)O!VM6NO:'?#,-U & /L58!E/J& (]*ZG.:_%O_ M (-K_P!J67P=\9_$7PEU6Z=;;Q! ][IL3M\JW4.6=%';,8D/U45^T8XKCXBR M9Y9CI86]X[I]T_ZL=G#>=+-,#'%6M+9KLU_5Q:AO]0@TJREN;J:*VMX%+R2R MN$2-1U))X ^M39Q7X@?\%K/^"B'C7]H/]I2X^"7@&XOH-$TN_32Y;>Q<.Y:,;O4 $> M]=.__!K7K&TX^+VGYQQG0FY/_?ZOIGDG#$'RSQLKKLM/_26?,+.^*)KGA@HV M?>6O_I2_(_5WX6?'?P9\;].-UX1\3:-X@B4;G^Q72R/&/]I/O+^(%=;7\_VG M?\$Z?VH_V"/VP_#^E?#^"\U75KB0W6GZCI,C?V9=Q)_K%N"^U4&T_,K#Q!DF'P+A4PM= M5835UW7JCW^'L[Q&/4Z>+H.E.#L^S]&;5%%%?-GTI7U72[?7--GL[N&.XM;I M#%+%(NY74C!!%?S[_P#!6_\ 8%U?_@G;^T]%XM\'M<0>#M>NSJ>B74 (.E3Y MW-;$]MK9V^JE>^:_H/->9?M=?LP^&_VN_@3K7@SQ-$OV2_A8PW.T;[&4 [95 M)Z$5]-PMG\LKQ?-+6G+22\N_JO\ @'S'%7#\*_P#! M(W_@H]8_MY_ .V75)H;?X@>'8Q:ZU:[O^/DCA;I!_=D&"1_"VX= "?KBOYC? M@3\8?$O_ 3K_;:DN/#.JVFMW/A?6I=*N&M)&-IK,23&-A[JV,CTSQ7],7A; M7/\ A)_"^G:EY$UI_:%K%<^1*,20[T#;6'J,X/TKMXSR"&7XF-;#_P *KK'R M[KTUT^XX>"N()YCAG1Q'\6EI+S[/UTU-"OCG_@M%^QAXU_;<_9[T;PYX'BTZ M74K/4QFI_\$_OV?+?Q/HNBVNM:KJ-ZMG MEU*4ABZ99@!D]>F1]:\+(I8E9A2>#2=2^E]K^9[V?1PTLOJK&MJG;WK;V\BO M_P $??V3?%W[&?[)$'@[QI'81ZQ'J-S<$6)JPCS2=W M:2/D<#QSD6$P\,-2E+E@K*\7T/W&HK\@?V/_ /@X(^*/[0O[3_@;P3J?A?PA M:Z=XFUBWT^XE@6;S421PI*Y;&1GTK]?0:^3SC(\5EE2-+%I)R5U9W/K_\ ,_26BBBOST_10K\&?^#D7_D^JU_[ MO_ .@K7[S5^#/_ M #?^P/;?^BUKMJXG]F[_ )(!X-_[ ]M_Z+6NVKXG$_QI>K_,^WPW\&'HOR"B MBBL3<^:O^"M?[4"_LJ?L,^-=:AE\O6-5LWT;2\'#>?+/BUJMOYD>G1-I6FM(O#RR_ZUQ]$WH?]^G_ /!QAX_\7_&7 MXP>&OASX:\.>)-4TKP[&+V[DM-/FEAFN9!A &5=ORJS ^]?HU_P3C_9C3]DC M]D#PAX0=%748+1;C465<;[F0 R'\Z_0G..6\-35M.1X].T/7HM;L548\^QD MDR\6?4QEE/\ O5_0EX&\7V?C_P &Z9K>GS)<66J6R7,,B'*NK $8K\Q/^#E_ M]ET^(?A;X9^*EA #/X?N!INILJ\^1,<(Y/M)L7_@5>P_\&_'[4'_ O+]BV' MPU>3;]7\ S#3W#/DM;D'R3Z]%.?J*UXA_P"%/(\/FJUG#W)_UZ_^E&7#G_"9 MGF)RIZ0G[\/Z]/\ TD^[CTK^>KP%/!9?\%U;%KTI'&/B#@F7H&+X7\=Q&/?% M?T*GI7XT?\%N/^"6WC3PI\;;KXV_#.QO-2L+^X6^U2"P4F\TN[5@1.BCED+ M?=Y4XX(R1Q<"8NA#$5L+6ER^U@XION=O'N$KSP]'%48\WLIJ32WL?LN#D4M? M@[\,_P#@XJ^.GPG\+P:%K^B>'=?N[!1$+J_MY;>[8#C]YAL$_P# 171#_@YS M^*V?^1(\&_3?-_C2EX=YPG:,8M=^9:A#Q&R9Q3DY)]N5G[?%1OSWZ9IU?F7^ MQ/\ \'&WA;XS^-['PS\3/#?_ A-WJ,BP6VKVUW]IL&D;[HE4JK1 G@,-XR1 MG R1^E]G=1WUK'-#(LL4RAT=3D,IY!!KYG-,GQF75/98R'*WMU3]&M#ZC*LY MP>8T_:X.?,EOT:]4]26BBBO,/4$)Q7YU?\%W/^"FP_9K^';_ Q\(7VWQOXD MM]U]/$_S:3:,/;_EHXZ>@P>7"01EB" M0H9B!G )Q[&ODGXK?\$]OV4_CE\0]5\5>*;K0-8UW69S<75U-XF7+,>@ $F MH [ "O>X>GA*.+CB,="4H1U22O=]+^1X'$4,76PDL/@9QC.6C;=K+K;S/@ M'_@A#_P3"D^/_CF+XM>.+)V\(:).6TJWF7_D+72GESG_ )9JW'?<0>F,U^XH M&!7G/PV\5_"[X0^!-*\,^'/$/@_2]$T2V2TL[6+58-L4:C 'W\D]R3R2236Y M_P +S\$_]#AX6_\ !M!_\76O$6:XK-<6Z\XM16D5;9?YOJ9<.91ALGW?\ EV.JK\X?^#EW_DSWPY_V&Q_):_0;PU\0-!\9RRIH^M:3JKP &5;. M\CG,8/3(4G'XU^?'_!RZ?^,/O#G_ &&Q_):KA*+6=8=/^;]">+I*62XAQ_E_ M5#?^" 7P)\%?$;]@:TO=>\*>']8O/[7NP;B\L(YI"!*P W,"<8K[=_X9(^%_ M_1/O"'_@JA_^)KXV_P"#>SX@Z!X8_P""?]I;ZCKFCV$_]K7C>5#3HDDB<D>+/,_LO5--U/R3B3[)*H=3UG2=.E?7RRI=7<< M+,/+'(#$5][1BWPA-+_GY_D? 5I)<8P;_P"??^9^G=%2>377\T?U/VP_9N_Y(!X-_[ ]M_Z M+6NVKRC]G;XN>%;3X$>#XI?$WAZ*1-(M@ROJ,(93Y8X(W5V?_"Y/"'_0U>&_ M_!G#_P#%5\9B:53VTO=>[Z>9]IAJU/V,/>6RZ^1TE4]?UZT\+:%>:GJ%Q%9V M&G0/=7,\APD,2*6=V/8!03^%8_\ PN3PA_T-7AO_ ,&'_ ;"?#,#_DH/B_\ \!X:^YQF M5\*X6O+#5JM3FCH[:Z_^ GPN"S3BO%4(XFC2I\LM5?33_P "-S]K/_@L'^S' M^U%^S?XR\!WOB#6%7Q%I&O@?\ MX*5_L.7/_!++]I[PM+X7U?4-0T]A#J^D7]U&$E2X@=6(.W@X;;Z<5[N1_P!A M5\/6RC 5)/VJ;M)=4MUHM>OR/!SUY[0Q%'.,?3BO9-*\7T;V>KTW7S/Z+QS2 M/&LB%6 92,$$9!%>>?LH?'.Q_:1_9V\)^--/8&'7-/BG90V3&^T;E/N#7A_[ M4G_!9_X-?LK?%VR\%:K?W^I:R;]+/5/L+ MK5Y8:C3!_"EU M.WWI'TN$LWU.WFJ3_LB_"Z1"I^'WA###!_XE+?#EW972"2*1-0BY!Y&06R#[&M#_A;'A8 G_A)= P/^HA#_\ %5'M,7'W M;R5O4T]GA)>]:+OZ'XT?\'!G_!/SP+^S+_PBOCWP-IZ: GB&^?3[_3H2?(:7 MRVD65,G*\(P(ZB\(>"Y]2N=$-PUZLM]<)/*[,D:9W(JC&V->WK7U& M8Y[#$Y'2P>(YG6C+=KIZ^A\KEV0SPV>5<9A^5491V3ZZ=/4]2HHHKXL^V/#O M^"A'[%EC^WC^SO<>"KO5)]&NH;H:EIUY&I80720RQ(74$;EQ,V1D=J_(S4?^ M#=S]I"SU&:*#6/!UQ"CD)*-9N5\Q>QQY/&?2OWAFE6",N[*J*,LS' KBD_: M3\ RZC+M!DN+)6>=([M6\I1U+$' ]:^JR+B7-,!2E1P:YH[V<;V_P"' M/D\_X;RK'58UL:^66U^:U_OWL?B;_P 0\O[2W_02\'_^#NY_^,4?\0\O[2W_ M $$O!_\ X.[G_P",5^X5_P#&KPGI>CIJ%SK^FP63Q"<3/, OEG[K'T![9ZT[ M2/C)X6U_5KBPL]=TZXO+3;Y\*R_/#N&5##L2", \U[7^ON=VYN16_P #/%_U M"R*_+[1W_P :/AS_ ((I?\$W/BA^PGXP\<7WQ!N=%GAU^UMX;3[#?27)#(S% MMV^-<<$>M>\_\%0_V%G_ &^OV:;CPG8ZG%I&N6DZWNG3SJ6A,B_P/CD*V ,C M./0U[KX>^(6A^++F6+3=6L;R6&:2W=(I0S!XR5=<=RI!!QT(-;6:^6Q>=XV> M8+,9^[55GM;;38^JP>28*&7/+J?O4G=;WWUW1^"]I_P;R_M+:7$8;?4_!T,0 M8D+%K=RJD^N!!4O_ !#Z_M._]!GPI_X/KK_XS7[Q@XHW5]%_Q$7->T/_ '_ M ()\[_Q#C*>\_P#P+_@'X.?\0^O[3O\ T&?"G_@^NO\ XS7WU_P1;_8#^)?[ M#FC>,X?B'=Z5=2ZY/'):FROI+D *J@YWHN.E?=).!2=J\_,^,\?C\-+"UU'E M=ME9Z?,]#*^"\OP&)CBJ#ES+N[K73L>$?\%'OV-C^W3^RSK?@6'44TG4;AH[ MJQN9$WQI/&P=0X!SM) !(Z#UK\CK3_@W@_:5TA6BMM3\&PINR1#K=RBM[\0" MOWHSQ2DUADW%F/RRB\/AVG%N]FKZF^<\)8#,ZRQ&(NI)6NG;0_!S_B'T_:=_ MZ#/A3_P?77_QFC_B'T_:=_Z#/A3_ ,'UU_\ &:_>/-+7K?\ $1DW1UOROLIL[^6ZQM MQG.]%QTKF?\ @LK_ ,$?O%O[''B;&QS%YG%I5'Y:6M;8]V7#&"EERRN2;IK7?7>^Y^#: M?\&^7[3D:*HUCPH !@ :]<\#_OS2_P#$/K^T[_T&/"G_ (/KK_XS7[QBEKW/ M^(BYKVA_X#_P3PO^(<93WG_X%_P#\&_^(?7]IW_H,>%/_!]=?_&:K7__ ;O M?M):L4%UJ'@RX"GY?.UJX?;^<%?O8#FCO1_Q$7->BA_X#_P0_P"(<93U<_\ MP+_@' ?LM_ >P_9F^ 'A;P/IX3R?#]A':LZC'G.J@,Y]R:] I,TM?#U:LJDW M4F[MN[^9]U2I0I05.FK)*R]$)7Q]_P %D?\ @GGJO[?7P$TVR\+'38O%_A_4 M$NK)[V1HHI(FRDL;.%8@;6+=.JBOL$G%!YKHP&.JX/$0Q-!VE%W1SYA@*6-P MT\+77NR5F?(/_!'3]ESXJ?L'M5'@[QYMQ-.;;SK35 .@E4%65O\ ;!/? M*MV^YQQ0W-=RS_&0QTLQHODJ2WMMYZ.^YP/A_!SP$C5/!WC*R M\0?&7QNVM6]BPE7P_I4TQM[AQR/-G<@E!W4("?[P[_J7IUA#I5A#;6\:Q06Z M".-%Z(H& *ESF@5\SFN=8O,:BJ8J5[;):)>B7_#GT^4Y)@\MINGA(VONWJWZ MO^D+1117E'K'R3_P6B^*FN?"G]C?SM!OI=/GUC6(],N98CM

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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 06, 2024
Entity File Number 001-33958
Entity Registrant Name SELLAS Life Sciences Group, Inc.
Entity Central Index Key 0001390478
Entity Tax Identification Number 20-8099512
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7 Times Square
Entity Address, Address Line Two Suite 2503
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10036
City Area Code 646
Local Phone Number 200-5278
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol SLS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sellaslifesciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sls-20240306.xsd sls-20240306_lab.xml sls-20240306_pre.xml tm248331d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm248331d1_8k.htm": { "nsprefix": "sls", "nsuri": "http://sellaslifesciences.com/20240306", "dts": { "schema": { "local": [ "sls-20240306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sls-20240306_lab.xml" ] }, "presentationLink": { "local": [ "sls-20240306_pre.xml" ] }, "inline": { "local": [ "tm248331d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://sellaslifesciences.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248331d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248331d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sellaslifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-032384-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-032384-xbrl.zip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end XML 17 tm248331d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001390478 2024-03-06 2024-03-06 iso4217:USD shares iso4217:USD shares false 0001390478 8-K 2024-03-06 SELLAS Life Sciences Group, Inc. DE 001-33958 20-8099512 7 Times Square Suite 2503 New York NY 10036 646 200-5278 false false false false Common Stock, $0.0001 par value per share SLS NASDAQ false